Severe Drug Eruptions

1. ARNOLD, R., SEIFERT, M., ASADULLAH, K., VOLK, H. D. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J. Immunol., 1999, 162, p. 7140–714.

2. BASTUJI-GARIN, S., FOUCHARD, N., BERTOCCHI, M. et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol., 2000, 115, p. 149–153.

3. BETTO, P., GERMI, L., BONOLDI, E., BERTAZZONI, M. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin-clavulanic acid. Int. J. Dermatol., 2008, 47, p. 295–296.

4. BIRNIE, A. J., LITLEWOOD, S. M. Acute generalized exanthematous pustulosis does not always have a drug-related cause. Br. J. Dermatol., 2008, 159, p. 492–493.

5. BOCQUET, H., BAGOT, M., ROUJEAU, J. C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin. Cutan. Med. Surg., 1996, 15, p. 250–257.

6. BREATHNACH, S. M. Erythema multiforme, Stevens- -Johnson syndrome and toxic epidermal necrolysis. In Burns, T., Breathnach, S., Cox, N., Griffiths, C. Rook’s Textbook of Dermatology. 8th ed., Wiley-Blackwell: Hoboken 2010.

7. CAMPIONE, E., MARULLI, G. C., CARROZZO, A. M. et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm. Veneol., 2003, 83, p. 430–432.

8. CETKOVSKÁ, P., PIZINGER, K., ŠTORK, J. Kožní změny u interních onemocnění. Grada: Praha 2011, 1. vydání, s. 213–222.

9. DIETRICH, A., KAWAKUBO, Y., RZANY, B. et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp. Dermatol., 1995, 4, p. 313–316.

10. EGAN, C. A., GRANT, W. J., MORRIS, S. E. et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J. Am. Acad. Dermatol., 1999, 40, 458–461.

11. ELZAGALLAAI, A. A., KNOWLES, S. R., RIEDER, M. J. et al. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Safety, 2009, 32, p. 391–408.

12. FERNANDO S. L. Acute generalized exanthematous pustulosis. Australas J Dermatol 2012, 55, p. 87-92.

13. FERRELL, P. B. Jr., McLEOD, H. L. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommentations. Pharmacogenomics, 2008, 9, p. 1543–1546.

14. FIROZ, B. F., HENNING, J. S., ZARZABAL, L. A., POLLOCK, B. H. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J. Am. Acad. Dermatol., 2012, 67, p. 630–635.

15. GARCIA-DOVAL, I., LeCLEACH, L., BOCQUET, H. et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol., 2000, 136, p. 323–327.

16. GUBERMAN, A. H., BESAG, F. M., BRODIE, M. J. et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia, 1999, 40, p. 985–991.

17. GUEGAN, S., BASTUJI-GARIN, S., POSZEPCZYNSKA--GUIGNE, E. et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J. Invest. Dermatol., 2006, 126, p. 272–276.

18. HALEVY, S., KARDAUN, S. H., DAVIDOVICI, B., WECHSLER, J. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br. J. Dermatol., 2010, 163, p. 1245–1252.

19. HUNG, S. I., CHUNG, W. H., LIOU, L. B. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci., USA 2005, 102, p. 4134–4139.

20. HUSAIN, Z., REDDY, B. Y., SCHWARTZ, R. A. DRESS syndrome. Part I. Clinical perspectives. J. Am. Acad. Dermatol., 2013, 68, p. e1–14.

21. HUSAIN, Z., REDDY, B. Y., SCHWARTZ, R. A. DRESS syndrome. Part II. Management and therapeutics. J. Am. Acad. Dermatol., 2013, 68, p. 709e1-9.

22. CHUNG, W. H., HUNG, S. I., HONG, H. S. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428, p. 486.

23. CHUNG, W. H., HUNG, S. I., YANG, J. Y. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Medicine, 2008, 14, p. 1343–1350.

24. KABASHIMA, R., SUGITA, K., SAWADA, Y. et al. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J. Eur. Acad. Dermatol. Venereol., 2011, 25, p. 485–488.

25. KARDAUN, S. H., JONKMAN, M. F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm. Venereol., 2007, 87, p. 144–148.

26. LEE, H. Y., CHOU, D., PANG, S. M. et al. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. Int. J. Dermatol., 2010, 49, p. 507–512.

27. MALLAL, S., NOLAN, D., WITT, C. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359, p. 727–732.

28. McCORMACK, M., ALFIREVIC, A., BOURGEOIS, S. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med., 2011, 364, p. 1134–1143.

29. MOCKENHAUPT, M., VIBOUD, C., DUNANT, A. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J. Invest. Dermatol., 2008, 128, p. 35–44.

30. NICKOLOFF, B. J. Saving the skin from drug-induced detachment. Nature Medicine, 2008, 14, p. 1311–1313.

31. OZEKI, T., MUSHIRODA, T., YOWANG, A. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepin-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet., 2011, 20, p. 1034–1041.

32. PAQUET, P., NIKKELS, A., ARRESE, J. E. et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch. Dermatol., 1994, 130, p. 605–607.

33. PAQUET, P., PIERARD, G. E. Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin Pharmacol. Physiol., 2007, 20, p. 66–70.

34. PEREIRA, F. A., MUDGIL, A. V., ROSMARIN, D. M. Toxic epidermal necrolysis. J. Am. Acad. Dermatol., 2007, 56, p. 181–200.

35. PRINS, C., KERDEL, F. A., PADILLA, R. S. et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch. Dermatol., 2003, 139, p. 26–32.

36. RASTOGI, S., MODI, M., DHAWAN, V. Acute localized exanthematous pustulosis (ALEP) caused by ibuprofen. A case report. Br. J. Oral. Maxillofac. Surg., 2009, 49, p. 132–134.

37. ROUJEAU, J. C. Clinical heterogeneity of drug hypersensitivity. Toxicology, 2005, 209, p. 123–129.

38. ROUJEAU, J. C., BIOULAC-SAGE, P., BOURSEAU, C. et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch. Dermatol., 1991, 127, p. 1333–1338.

39. ROUJEAU, J. C. Neutrophilic drug eruption. Clin. Dermatol., 2000, 18, p. 331–337.

40. SCHNECK, J., FAGOT, J. P., SEKULA, P. et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J. Am. Acad. Dermatol., 2008, 58, p. 33–40.

41. SCHWARTZ, R. A., McDONOUGH, P. H., LEE, B. W. Toxic epidermal necrolysis. Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J. Am. Acad. Dermatol., 2013, 69, p. 173e1-13.

42. SCHWARTZ, R. A., McDONOUGH, P. H., LEE, B. W. Toxic epidermal necrolysis. Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J. Am. Acad. Dermatol., 2013, 69, p. 187e1-16.

43. SIDOROFF, A., DUNANT, A., VIBOUD, C. et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br. J. Dermatol., 2007, 157, p. 989–996.

44. SIDOROFF, A., HALEVY, S., BAVINCK, J. N. et al. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J. Cutan. Pathol., 2001, 28, p. 113–119.

45. SPEECKAERT, M. M., SPEECKAERT, R., LAMBERT, J., BROCHEZ, L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur. J. Dermatol., 2010, 20, p. 425–433.

46. TAS, S., SIMONART, T. Drug rash with eosinophilia and systemic symptoms (DRESS). Acta Clin. Belg., 1999, 54, p. 197–200.

47. TENNIS, P., STERN, R. S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology, 1997, 49, p. 542–546.

48. UETA, M., SOTOZONO, C., INATOMI, T. et al. Association of IL4R polymorphisms with Stevens-Johnson syndrome. J. Allergy Clin. Immunol., 2007, 120, p. 1457–1459.

49. UM, S. J., LEE, S. K., KIM, Y. H. et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J. Investig. Allergol. Clin. Immunol., 2010, 20: 556–562.

50. UMAYAHARA, T., SHIMAUCHI, T., FUJIYAMA, T. et al. Paediatric acute generalized exanthematous pustulosis induced by paracetamol with high serum levels of interleukin-8 and -22: A case report. Acta Derm. Venereol., 2013, 93, p. 362–363.

51. VALEYRIE-ALLANORE, L., BASTUJI-GARIN, S., GUÉGAN, S. et al. Prognostic value of histologic features of toxic epidermal necrolysis. J. Am. Acad. Dermatol., 2013, 68, p. e29-35.

52. VALEYRIE-ALLANORE, L., WOLKENSTEIN, P., BROCHARD, L. et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br. J. Dermatol., 2012, 163, p. 847–853.

53. WOLFF, K., JOHNSON, R. A. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 6th ed., McGraw- -Hill: Columbus 2009, p. 552–581.

54. WORSWICH, S., COTLIAR, J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol. Ther., 2011, 24, p. 207–218.